Crinetics Pharmaceuticals

Yahoo Finance • 4 days ago

[Latest] Global Bioprocess Automation Software Market Size/Share Worth USD 6.19 Billion by 2035 at a 14 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Bioprocess Automation Software Market size & share revenue was valued at approximatel... Full story

Yahoo Finance • 12 days ago

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?

Key Points ADAR1 Capital Management added 829,963 shares of Crinetics Pharmaceuticals; estimated trade size $37.07 million based on quarterly average pricing. Quarter-end position value increased by $26.98 million, reflecting both trading... Full story

Yahoo Finance • 28 days ago

Crinetics Pharmaceuticals (CRNX): Billionaire Tom Steyer Likes This Pharma Stock

We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ranks 6th on this list. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) first appeared in the 13F portfolio... Full story

Yahoo Finance • last month

Crinetics Pharmaceuticals (CRNX) is One of the Best Biotech Stocks to Buy, Here is Why

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 best biotech stocks with highest upside potential. As of the April 24 closing, the stock carries a strongly bullish consensus sentiment. With a price target of $86.71, it yield... Full story

Yahoo Finance • last month

Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer

Ms. Deardorf is an experienced biopharma leader who will lead business development and corporate and commercial strategy as Neutrolis advances NTR-1011 into autoimmune diseases following positive Phase 1a results CAMBRIDGE, Mass., April... Full story

Yahoo Finance • 2 months ago

Crinetics Pharmaceuticals Solicita Autorização de Comercialização de Palsonify™ (Paltusotina) no Brasil para Tratamento de Acromegalia

SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- A Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) anunciou hoje que deu entrada em um Pedido de Autorização de Comercialização (MAA) à Agência Nacional de Vigilância Sanitária (ANVISA) do Bras... Full story

Yahoo Finance • 2 months ago

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil’s National Health Surveillance Agency (ANVISA) for PALSO... Full story

Yahoo Finance • 3 months ago

This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough

On February 17, 2026, Driehaus Capital Management disclosed a buy of Xenon Pharmaceuticals(NASDAQ:XENE), adding 369,577 shares in an estimated $15.52 million trade based on quarterly average pricing. What happened According to an SEC fil... Full story

Yahoo Finance • 3 months ago

Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know

Driehaus Capital Management disclosed a significant buy of Eos Energy Enterprises(NASDAQ:EOSE) in its February 17, 2026, SEC filing, adding 7.70 million shares in an estimated $110.72 million trade based on quarterly average pricing. What... Full story

Yahoo Finance • 3 months ago

Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight

The dynamics of the acromegaly market are anticipated to change due to extensive R&D, the entry of novel therapies such as Debio 4126 (Debiopharm International SA), ALXN2420 (AstraZeneca), MAR002 (Marea Therapeutics), Paltusotine (Crinetic... Full story

Yahoo Finance • 5 months ago

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 44th Annual J.P. Morgan... Full story

Yahoo Finance • 6 months ago

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the CALM-CAH Phase 3 trial evaluating investigational candidate atumelnant, a novel, onc... Full story

Yahoo Finance • 6 months ago

Crinetics Pharmaceuticals (CRNX) Poised for Transformational Growth in 2026: Piper Sandler

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Piper Sandler reiterated that Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the stocks to own... Full story

Yahoo Finance • 6 months ago

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somat... Full story

Yahoo Finance • 6 months ago

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet needs in the neuroendocrine tumor community SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSW... Full story

Yahoo Finance • 7 months ago

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purc... Full story

Yahoo Finance • 7 months ago

Crinetics Pharmaceuticals Inc Q3 Loss Increases, Misses Estimates

(RTTNews) - Crinetics Pharmaceuticals Inc (CRNX) reported Loss for its third quarter that increased from the same period last year and missed the Street estimates. The company's earnings came in at -$130.09 million, or -$1.38 per share.... Full story

Yahoo Finance • 8 months ago

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purch... Full story

Yahoo Finance • 8 months ago

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes. Company managemen... Full story

Yahoo Finance • 8 months ago

Stocks Finish Higher as Core PCE Prices Match Expectations

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) on Friday closed up +0.59%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/f... Full story